RT Journal Article
SR Electronic
T1 The Role of Modelling and Analytics in South African COVID-19 Planning and Budgeting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.23.22279123
DO 10.1101/2022.08.23.22279123
A1 Meyer-Rath, Gesine
A1 Hounsell, Rachel A
A1 Pulliam, Juliet RC
A1 Jamieson, Lise
A1 Nichols, Brooke E
A1 Moultrie, Harry
A1 Silal, Sheetal P
YR 2022
UL http://medrxiv.org/content/early/2022/08/25/2022.08.23.22279123.abstract
AB Background The South African COVID-19 Modelling Consortium (SACMC) was established in late March 2020 to support planning and budgeting for COVID-19 related healthcare in South Africa. We developed several tools in response to the needs of decision makers in the different stages of the epidemic, allowing the South African government to plan several months ahead of time.Methods Our tools included epidemic projection models, several cost and budget impact models, and online dashboards to help government and the public visualise our projections, track case development and forecast hospital admissions. Information on new variants, including Delta and Omicron, were incorporated in real time to allow the shifting of scarce resources when necessary.Results Given the rapidly changing nature of the outbreak globally and in South Africa, the model projections were updated regularly. The updates reflected 1) the changing policy priorities over the course of the epidemic; 2) the availability of new data from South African data systems; and 3) the evolving response to COVID-19 in South Africa such as changes in lockdown levels and ensuing mobility and contact rates, testing and contact tracing strategies, and hospitalisation criteria. Insights into population behaviour required updates by incorporating notions of behavioural heterogeneity and behavioural responses to observed changes in mortality. We incorporated these aspects into developing scenarios for the third wave and developed additional methodology that allowed us to forecast required inpatient capacity. Finally, real-time analyses of the most important characteristics of the Omicron variant first identified in South Africa in November 2021 allowed us to advise policymakers early in the fourth wave that a relatively lower admission rate was likely.Conclusion The SACMC’s models, developed rapidly in an emergency setting and regularly updated with local data, supported national and provincial government to plan several months ahead of time, expand hospital capacity when needed, allocate budgets, and procure additional resources where possible. Across four waves of COVID-19 cases, the SACMC continued to serve the planning needs of the government, tracking waves and supporting the national vaccine rollout.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work of GMR and LJ on the SACMC was supported by USAID South Africa (EVIDENCE) and USAID (EQUIP). SPS, RAH and the development of the SACMC dashboards are funded by the Wellcome Trust (GN: 2114236/Z/18Z) and the Clinton Health Access Initiative. JRCP is supported by the Department of Science and Innovation and the National Research Foundation. Any opinion, finding, and conclusion or recommendation expressed in this material is that of the authors, and the NRF does not accept any liability in this regard. The SACMC’s work is also supported by the Bill & Melinda Gates Foundation under Investment INV-035464. The views and opinions expressed in this report do however not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll data are available in publicly accessible reports under https://sacmcepidemicexplorer.co.za/. https://sacmcepidemicexplorer.co.za/